Analytical Data
-
基因名
NY-SAR-48
- Application
-
别名
DGT4; HAUS augmin like complex subunit 8; HAUS augmin-like complex subunit 8; HAUS8; HAUS8_HUMAN; Hec1 interacting and centrosome associated 1; HEC1/NDC80 interacting centrosome associated protein 1; HEC1/NDC80-interacting centrosome-associated protein 1; HICE 1; HICE1; MGC20533; NY SAR 48; NY-SAR-48; Sarcoma antigen NY SAR 48; Sarcoma antigen NY-SAR-48
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9BT25
-
表达区间
2-410 aa
-
氨基酸序列
ADSSGRGAG KPATGPTNSS SAKKKDKRVQ GGRVIESRYL QYEKKTTQKA PAGDGSQTRG KMSEGGRKSS LLQKSKADSS GVGKGDLQST LLEGHGTAPP DLDLSAINDK SIVKKTPQLA KTISKKPEST SFSAPRKKSP DLSEAMEMME SQTLLLTLLS VKMENNLAEF ERRAEKNLLI MCKEKEKLQK KAHELKRRLL LSQRKRELAD VLDAQIEMLS PFEAVATRFK EQYRTFATAL DTTRHELPVR SIHLEGDGQQ LLDALQHELV TTQRLLGELD VGDSEENVQV LDLLSELKDV TAKKDLELRR SFAQVLELSA EASKEAALAN QEVWEETQGM APPSRWYFNQ DSACRESGGA PKNTPLSEDD NPGASSAPAQ ATFISPSEDF SSSSQAEVPP SLSRSGRDLS
-
分子量
44.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant Human ACAD10 Protein，GST
Cat：PA2000-5319
Recombinant Human AHCYL1 Protein，His
Cat：PA2000-1236
Protein Description
NY-SAR-48 is a recombinant protein that has garnered significant attention in cancer research, particularly for its potential as a targeted therapeutic agent. Initially discovered in the context of melanoma, NY-SAR-48 consists of a modified murine interleukin-2 (IL-2) fused with a single-chain variable fragment (scFv) derived from a tumor-specific antibody. This design aims to enhance the targeting of immune responses towards tumor cells while minimizing effects on healthy tissues. The background of this research is rooted in the need for more effective cancer treatments that can elicit strong immune responses specifically against cancer cells. Traditional therapies often come with severe side effects due to non-specific activity, leading to the exploration of more refined immunotherapeutic strategies. NY-SAR-48 is particularly interesting because it combines the potent immune-stimulating properties of IL-2 with the specificity of an antibody fragment, laying the groundwork for personalized cancer immunotherapy. In preclinical studies, NY-SAR-48 has shown promising results in activating T cells and enhancing anti-tumor immunity, indicating its potential role in combination with other treatments such as checkpoint inhibitors. Continued research is focused on elucidating its mechanisms of action, optimizing dosing regimens, and evaluating clinical efficacy through forthcoming trials. As such, NY-SAR-48 represents a significant advancement in the ongoing quest to develop more effective and safer therapeutic options for cancer patients.
